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Introduction: Our recent data revealed frequent routine surveillance endoscopy and biopsy (E&B) did not have clinical benefit after intestinal transplantation (ITX). After abandoning protocol E&B, average frequency of E&B
during the first year was 2 times and ITX without stoma became a default
practice at our center. Occasionally, however, there were patients who presented concerning symptoms repeatedly, requiring extraordinary numbers of
E&B. Herein, we attempted to identify pre- and peri-transplant factors, which
might impact on the frequency of E&B.
Methods: Study group included all forms of ITX from 2012 to 2019 performed at a single center. The primary end point was E&B frequency in one
year. Univariate regression analysis was performed using negative binomial
distribution to identify pre- and peri-transplant risk factors for E&B frequency.
Wald test was used with p<0.2.
Results: E&B was performed 0 to 13 times in 59 patients during the first year
after ITX. Median number of E&B was 2. Low donor-recipient body weight
ratio, high degree of anti-human leukocyte antigen mismatch, high calculated
panel reactive antigen, more donor specific anti-human leukocyte antigen
antibody (DSA), and positive physical cross match (XM) were related to more
frequent E&B. Re-ITX, presence of DSA with high mean fluorescence intensity (>10000), positive virtual XM, long cold ischemia time, absence of the
liver graft were not related to frequent E&B as well as mismatch between
donor and recipient for cytomegalovirus, ABO blood group, and sex.
Conclusions: This result suggests immunologic incompatibility between
donor and recipient impacts on the development of concerning symptoms
to indicate E&B. Though all E&B in such cases did not reveal acute rejection.
Positive physical XM could be considered as an indicator to create stoma to
provide easy access for probable frequent E&B. Interestingly, factors considered as a high risk ITX such as positive virtual XM, isolated ITX without liver
graft, re-ITX, and long cold ischemia time were not related to frequent E&B
and therefore do not necessarily mandate to create the stoma.

Background: With only 81 intestine transplant (IT) in the U.S. in 2019, the
literature on this type of solid organ transplant remains scarce. Frequent surveillance biopsy is required on the first month post IT due to high-risk of acute
rejection, however, the frequency of surveillance biopsy 1-month post IT is
often determined by the physician and the institutions’ preference.
Aims: Report IT outcomes and clinical impact of surveillance biopsy at a
single tertiary care center.
Methods: This is a retrospective review of patients that underwent IT during
the time-period between 08/2010 and 03/2020. Primary outcome was the
correlation between increased protocol biopsies and mortality. Secondary
outcomes included correlation between increased protocol biopsies and
hospital re-admissions, length of hospital stay, and rate of biopsy proven
rejection detection. Kaplan-Meier curves was used to perform the survival
analysis at 6-month, 1-year, and 2-years post-transplant.
Results: A total of 35 patients (mean age 47.6 ± 12.9 years, F 22 (63%)
underwent IT for: ischemic bowel 11 (31%), Chron’s disease 9 (25%), neuroendocrine tumor 6 (17%), trauma 3 (9%) and “others” 6 (17%), of which 14
(40%) were part of multivisceral organ transplant. During the first-year posttransplant, the median number of biopsies was 12 (IQR 6-30), with evidence
of definite acute graft rejection in 40%, 27%, and 41% at the 1-3, 3-6, and
6-12 post IT time intervals, respectively. During the duration of the study, the
mortality rate was 18/35 (51%) at a median time of 37 (12-60) months post
IT, and a total of 8/35 (23%) patients underwent enterectomy at a median
time of 12 (8-36) months post IT (Table 1). In general, there was survival
benefit for patients who had a total number of biopsies of ≥ 10 as compared
to < 10 biopsies at the time interval of 6-months post IT, (p=0.008) (Table 2).
There was a non-significant trend with longer median length of hospital stay
in patients with greater number of biopsies.
Conclusion: Our results indicate evidence of survival benefit of increased
protocol biopsies. Studies with larger sample sizes are required to validate
our results.

